Kaya Ltd

- Kaya Limited is planning a rights issue for fundraising, with a substantial amount of around Rs. 300 Crores mentioned. - The exact timing and details of the rights issue are not disclosed yet as the company is still working on submissions and approvals. - The rights issue committee is already in place and once filed with authorities, information will be made public. - The raised funds are expected partly to be used for debt reduction and expansion in India and overseas, but precise plans are not finalized. - No clear guidance on future debt raising or other equity fundraisings beyond the rights issue was provided. - The company is cautious on commenting further until formal processes complete.

- Capex per clinic is approximately Rs. 1.5 Crore, including machines. (Page 9) - Expansion focused on Tier-2 cities and peripheral regions with opportunistic clinic openings where rental costs are favorable (e.g., Lucknow, Surat, Siliguri, Electronic City Bangalore). (Pages 5, 9, 12) - Rights issue fundraising planned (~Rs. 300 Crores) with utilization details and timing currently not disclosed; intended partly for expansion and possibly debt reduction. (Pages 6-7) - No immediate plans to set up peripheral businesses like laboratory sample collection; collaborations and tie-ups are preferred for diagnostics and related services. (Page 5) - D2C (Direct-to-Consumer) business platform launched and integrated with clinics to supply products within a day, indicating investment in digital capabilities. (Page 14) - No forward-looking specific capex or strategic investment guidance provided currently. (Pages 14-15)

- Kaya India clinics achieved strong 20% growth in Q2 FY2024 versus last year. - New growth levers (body category, nutraceuticals, innovation, omni-channel, new clinics) contributed 63% of growth. - Clinic net revenue grew 21%, product business grew 34% (notably skin and nutraceuticals). - Renewed focus on hair care category drove 24% growth. - Expansion into Tier-2 cities and peripheral regions is underway (e.g., Surat, Lucknow, Siliguri, Electronic City Bangalore). - Clinic business growing at about 18% for centers operational over two years. - Capacity utilization in clinics is being increased from current ~55-70%. - D2C business growing, with improved integration between clinics and online sales. - Middle East business (especially UAE) showing growth; UAE clinic EBITDA ~30%. - Management cautious with forward-looking guidance but aims for sustainable EBITDA growth and expansion driven by new clinics and categories.

- The company currently does not provide explicit forward-looking guidance on EBITDA or profits but emphasizes aiming for sustainable EBITDA levels to drive profitability (Page 14, Saurabh Shah). - Clinic EBITDA is around 27%, with corporate level EBITDA at approximately 2%, indicating potential room for margin improvement (Page 14). - Growth levers include expansion into new segments like hair care and nutraceuticals, which have shown strong contributions recently (Page 14). - The D2C business is being promoted strongly, integrating with clinics for faster delivery, potentially increasing product revenue share over time (Page 14). - Clinic expansion focused on Tier-2 and peripheral regions with better profitability potential is ongoing (Page 9 and 12). - Utilization improvements (currently ~55-70%) through better machine deployment aim to increase revenue per clinic (Page 6). - Rights issue proceeds (Rs. 300 Crores) are expected to support expansion and debt reduction, but detailed utilization timelines are pending (Page 7).

The provided transcript and document pages do not contain any specific information regarding Kaya Limited's current or expected order book or pending orders. The discussion mostly focuses on operational performance, clinic growth, unit economics, customer journey, regional market performance, capital expenditure per clinic, and rights issue fundraising. There is no mention or data shared about order books or pending orders.